Allogeneic Plasmacytoid Dendritic Cells Expressing Lung Tumor Antigens PDC*lung01

**Semantic type:** Cell|Immunologic Factor|Pharmacologic Substance

**Definition:** An off-the-shelf (OTS) preparation composed of irradiated allogeneic plasmacytoid dendritic cells (pDCs) loaded with seven immunogenic, human leukocyte antigen (HLA)-A*02:01 serotype-restricted peptides derived from the lung tumor antigens cancer/testis antigen 1 (NY-ESO-1), melanoma antigen A3 (MAGE-A3), MAGE-A4, multi-MAGE, a peptide shared by multiple MAGE-A proteins, survivin, mucin1 (MUC1) and melanoma antigen recognized by T-cells 1 (Mart-1; Melan-A), with potential immunostimulating and antineoplastic activities. Upon administration of the allogeneic pDCs expressing lung tumor antigens PDC*lung01, the pDCs may activate the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against HLA-A*0201 positive lung cancer cells expressing the TAAs NY-ESO-1, MAGE-A3, MAGEA4, multi-MAGE, survivin, MUC1 and melan-A. The pDCs are derived from a distinct subset of dendritic cells (DCs) with a plasma cell-like morphology and express a characteristic set of surface markers and may increase the anti-tumor immune responses.

**Synonyms:** - Allogeneic pDCs- expressing Lung Tumor Antigens PDC*lung01 - PDC*lung01 - PDClung01 - Therapeutic Cancer Vaccine PDC*lung01